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Background. Infection is a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT).
Our object was to better define the epidemiology and outcomes of infections after HCT.
Methods. This was a prospective, multicenter cohort study of HCT recipients and conducted from 2006 to 2011. The study
included 4 US transplant centers and 444 HCT recipients. Data were prospectively collected for up to 30 months after HCT using a
standardized data collection tool.
Results. The median age was 53 years, and median follow up was 413 (range, 5–980) days. The most common reason for HCT
was hematologic malignancy (87%). The overall crude mortality was 52%. Death was due to underlying disease in 44% cases and
infection in 21%. Bacteremia occurred in 231 (52%) cases and occurred early posttransplant (median day 48). Gram-negative
bloodstream infections were less frequent than Gram-positive, but it was associated with higher mortality (45% vs 13%, P = .02).
Clostridium difficile infection developed in 148 patients (33%) at a median of 27 days post-HCT. There were 53 invasive fungal infections (IFIs) among 48 patients (11%). The median time to IFI was 142 days. Of 155 patients with cytomegalovirus (CMV) infection,
4% had CMV organ involvement. Varicella zoster infection (VZV) occurred in 13 (4%) cases and was disseminated in 2. Infection
with respiratory viruses was seen in 49 patients. Pneumocystis jirovecii pneumonia was rare (1%), and there were no documented
cases of nocardiosis, toxoplasmosis, endemic mycoses, or mycobacterial infection. This study lacked standardized antifungal and
antiviral prophylactic strategies.
Conclusions. Infection remains a significant cause of morbidity and mortality after HCT. Bacteremias and C difficile infection
are frequent, particularly in the early posttransplant period. The rate of IFI is approximately 10%. Organ involvement with CMV is
infrequent, as are serious infections with VZV and herpes simplex virus, likely reflecting improved prevention strategies.
Keywords. infections; prospective; stem cell; transplant.

More than 8000 allogeneic hematopoietic cell transplants
(HCTs) are performed annually in North America. Significant
strides have been made in the last few decades to decrease
the incidence of serious infections, such as those due to cytomegalovirus (CMV) and varicella zoster virus (VZV), but infection remains a leading cause of morbidity and mortality after
HCT [1–5]. The types of patients receiving HCT, as well as the
conditioning regimen used, and the source of stem cells and
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immunosuppressive regimens used, differ across institutions
and have changed over time. Prospectively collected data from
multiple, geographically diverse centers are vital to the understanding of infectious complications and to the development of
prophylactic and treatment strategies. No multicenter studies
have prospectively evaluated the epidemiology, risk factors,
and outcomes of all infectious complications after HCT. Most
studies have been from single institutions or have focused on
specific types of infections [1–4, 6–9]. We created the Organ
Transplant Infection Project (OTIP), a network of 6 collaborating transplant centers, in 2006 to prospectively collect data
on all infectious complications and to investigate a variety of
potential risk factors and outcomes in a cohort of all allogeneic HCT recipients and lung transplant recipients over a 5-year
period. This report examines the HCT population only.
METHODS

The OTIP is a network of 6 collaborating transplant centers
(University of Pennsylvania, University of Michigan,
Infections After Hematopoietic Cell Transplant • OFID • 1
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Statistical Methods

Data collected by the OTIP centers were transmitted to the
CDC via an electronic case report form. Categorical variables
were analyzed using χ2 tests or Fisher’s exact tests, as appropriate. In all analyses, a 2-tailed level of significance was set to
α = 0.05. All analyses were done using SAS 9.3 (SAS Institute,
Inc., Cary, NC).
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Role of the Funding Source

The CDC developed the data collection tool and served as the
central unit for data processing and analysis.
RESULTS

During 2006–2011, we enrolled 444 allogeneic HCTs among
431 patients at 4 US transplant centers (153 from University of
Michigan Healthcare System, 24 from University of Alabama,
60 from University of Pennsylvania, and 207 from Washington
University); 431 patients had 1 transplant, 12 patients had 2
transplants, and 1 patient had 3 transplants. This represents 48%
of all patients who recieved transplants during the enrollment
period. Enrollment rates across the 4 different centers ranged
from 32% to 57%. The median age was 53 years (range, 18–75),
and the median duration of follow up was 413 days (range,
5–980) (Table 1). The most common indication for HCT was
hematologic malignancy (87%). Most of the transplants were
from matched, unrelated donors (55%) or from matched,
related donors (40%) (Table 2). The conditioning regimen was
myeloablative in 72%, and the source of hematopoietic cells was
peripheral blood in 87%. Relapsed malignancy was present at
the time of HCT in 113 (26%) of patients. The median time to
engraftment was 12 days (0–101).
Immunosuppression and Antimicrobial Prophylaxis

Most patients received tacrolimus for immunosuppression.
Graft-versus-host disease (GVHD) developed in 339 (76%)

Table 1. Organ Transplant Infection Project (2006–2011): Characteristics
of 444 Hematopoietic Cell Transplant Patientsa
Characteristic
Total cases
Median age, years

n

(Percent or Range)

444

(100)

53

(18–75)

Male sex

256

(58)

White race

421

(95)

Median days of follow up

413

(5–980)

Indication for Transplant
Hematologic malignancy
Acute myelogenous leukemia

387

(87)

180

(41)
(18)

Non-Hodgkins lymphoma

79

Acute lymphocytic leukemia

41

(9)

Chronic myelogenous leukemia

24

(5)

Hodgkin’s disease
Other hematologic disease

9

(2)

57

(13)

Myelodysplastic syndrome

41

(9)

Other indications

16

(3)

112

(25)

Comorbidities
Cardiovascular disease

a

Type 1 diabetes

31

(7)

Type 2 diabetes

20

(5)

Pulmonary disease

29

(7)

Splenectomy

7

(2)

Chronic kidney disease

5

(1)

A total of 444 transplants in 431 patients.
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Washington University in St. Louis, Cleveland Clinic, University
of Pittsburgh, University of Alabama at Birmingham), in collaboration with the Centers for Disease Control and Prevention
(CDC). Four centers (University of Michigan, University
of Alabama, University of Pennsylvania, and Washington
University) contributed patients undergoing HCT to the current study. Data were prospectively collected from each of the
centers during 2006–2011. All sites received local institutional
review board approval before patient enrollment. Patients were
followed for up to 30 months posttransplant. Study visits were
performed weekly for the first 4 months and during inpatient
stays, and monthly thereafter.
All patients ≥18 years of age who underwent allogeneic HCT
at the 4 sites were eligible for enrollment. Data collected at
enrollment included demographic information, details about
the transplant donor type (related or unrelated), graft source
(bone marrow, peripheral stem cells, or umbilical cord stem
cells), human leukocyte antigen match, conditioning regimen,
and immunosuppression as well as recipient comorbidities.
Use of antifungal and antiviral prophylaxis and empiric therapy for neutropenic fever was at the discretion of each center.
Antifungal prophylaxis was defined as follows: the use of a systemic antifungal agent for at least 7 days in the absence of a suspected or confirmed invasive fungal infection (IFI). Antiviral
prophylaxis was defined as use of an antiviral agent for at least
7 days in the absence of a suspected or confirmed viral infection.
Infectious syndromes were defined using Modified National
Nosocomial Infection Surveillance System (restructured in 2005
to become National Healthcare Safety Network) definitions [10].
Suspected infections other than CMV or IFI were defined as
any clinical syndrome for which antimicrobial treatment was
initiated. Cytomegalovirus infection was defined as detection
of CMV in the blood by polymerase chain reaction or pp65
antigenemia testing, positive histopathology, or a positive CMV
immunostain on a tissue biopsy. Infection onset date was considered to be the date of the first diagnostic culture or test, or
if the diagnosis date was unknown, the symptom onset date.
An infection was considered new if it occurred at least 2 weeks
after the resolution of a previous episode. Invasive fungal infections were defined according to the European Organization
for Research and Treatment of Cancer/Mycoses Study Group
(EORTC/MSG) criteria [11]. An adjudication committee, consisting of 5 study investigators, reviewed each reported IFI and
included only those that were proven or probable by the 2008
EORTC/MSG criteria [11].

Table 2.

Type of Transplant and Conditioning Regimen in 444 Patients

Characteristic

(%)

Matched, unrelated

245

(55)

Matched, related

177

(40)

20

(5)

Mismatched, related

2

(1)

Tandem

8

(2)

Transplant Type

Mismatched, unrelated

Transplant Source
Peripheral blood

Characteristic

N

(Percent or Range)

Gram positive

244

(56)

Coagulase-negative staphylococci

125

(51)

Vancomycin-resistant Enterococcus

41

(17)

Enterococcus faecium

31

(13)

Methicillin-susceptible Staphylococcus
aureus

17

(7)

386

(87)

Enterococus faecalis

8

(3)

Bone marrow

53

(12)

Methicillin-resistant S aureus

7

(3)

Umbilical cord

5

(1)

β-hemolytic streptococci

4

(2)

T-cell depleted

2

(<1)

Other

8

(3)

319

(72)

Gram negative

93

(21)

Pseudomonas aeruginosa

24

(26)

388

(87)

Escherichia coli

20

(22)

90

(20)

Klebsiella pneumonia

20

(22)

Stenotrophomonas maltophilia

6

(7)

Citrobacter freundii

5

(5)

Enterobacter cloacae

5

(5)

Acinetobacter baumanii complex

3

(3)

Burkholderia cepacia

2

(2)

Other

8

(9)

50

(12)

Myeloablative conditioning regimen
Immunosuppressiona
Tacrolimus
Cyclosporine
a

At any time posttransplant.

patients. Use of antiviral prophylaxis at some point after HCT
was as follows: acyclovir (70%), valacyclovir (40%), valganciclovir (4%), and ganciclovir (1%). Antifungal prophylaxis was
used in 368 patients (83%). Medications used as antifungal
prophylaxis during the posttransplant period included the following: fluconazole (53%), voriconazole (35%), caspofungin
(5%), posaconazole (3%), amphotericin B (<1%), and itraconazole (<1%). Trimethoprim-sulfamethoxazole (59%), dapsone
(29%), and atovaquone (7%) were used for prophylaxis against
Pneumocystis jiroveci.
Syndromes and Bacterial Infections

Infection occurred in 415 (93%) of transplants. Bloodstream
infections were the most common site, occurring in 231 (56%)
of 410 patients who had an infection (56%). Median time to
first bloodstream infection was 48 days (0–847). Bacteremias
were caused by Gram-positive bacteria in 244 (56%), Gramnegative bacteria in 93 (21%), and were polymicrobial in 50
(12%). The majority of Gram-positive bacteremias were caused
by coagulase-negative staphylococci and enterococci (Table 3).
Pseudomonas aeruginosa was the most frequent cause of Gramnegative bacteremia (26%) (Table 3). Anaerobic bloodstream
infections were rare, with only 1 case of Bacteroides fragilis bacteremia reported. Mortality within 7 days of bacteremia was
significantly higher for Gram-negative pathogens (45%) than
Gram-positive pathogens (13%) (P = .02).
Clostridium difficile was the most common bacterial pathogen causing infection. There were 198 episodes of C difficile
infection (CDI) in 148 patients (33%). Most patients (110
[74%]) had a single episode, although recurrent CDI developed
in 38 (26%). The median time to CDI was 27 days posttransplant. Clostridium difficile infection occurred after 118 (37%) of
319 myeloablative transplants versus 30 (24%) of 125 non-myeloablative transplants (odds ratio [OR], 1.6; 95% confidence

Polymicrobialb
a

Infection level data (n = 437), some patients had more than 1 infection.

b

Gram positive plus Gram negative.

interval [CI], 1.1–2.3). Of the 148 patients with CDI, 93 (63%)
ultimately died, compared with 138 (47%) of those without
CDI infection (OR, 1.9; 95% CI, 1.3–2.9). No infections with
Nocardia or mycobacterial species were identified.
Pneumonia developed in 132 (30%) patients. Of the 75
episodes in which a pathogen was identified, 38 (51%) were
bacterial, 26 (35%) were fungal, and 11 (15%) were viral. The
mortality rate for patients with pneumonia was 62.1% compared with 47.8% for those who never developed pneumonia
(OR, 1.79; 95% CI, 1.18–2.72). There were 136 symptomatic
urinary tract infections among 89 (20%) patients. Sinusitis
occurred in 30 (7%) patients. Only 6 episodes of sinusitis had
a microbiologic diagnosis: 2 bacterial and 4 fungal (mucorales
n = 2, Alternaria n = 1).
Viral Infections

Viral infections are displayed in Table 5. Cytomegalovirus was the
most common viral infection (154 patients, 35%). Most episodes
were limited to viremia, but organ involvement developed in 6
(4%) patients including the following: 4 with enteritis, 1 with hepatitis, and 1 with pneumonia. Infection with respiratory viruses
occurred in 49 (11%) patients. Of 18 patients with parainfluenza
infection, there were 8 episodes of pneumonia or other lower respiratory tract infection. Of the 15 patients with influenza infection, 6 had pneumonia or other lower respiratory tract infection.
Among 13 patients with respiratory syncytial virus infection,
there were 6 episodes of pneumonia or other lower respiratory
tract infection. Of the 6 patients with adenovirus infections, 2
Infections After Hematopoietic Cell Transplant • OFID • 3
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n

Table 3. Bacterial Bloodstream Infections in 444 Hematopoietic Cell
Transplant Recipients

Table 4. Proven and Probable Invasive Fungal Infections in 444
Hematopoietic Cell Transplant Recipientsa
Fungal Organisms

n

(%)

Candida

18

(34)

Aspergillus

17

(32)

Mucorales

7

(13)

Pneumocystis jiroveci

3

(6)

2

(4)

1

(2)

Mixed

3

(6)

Outcomes in 444 Hematopoietic Cell Transplant Recipients

Characteristic

n

Median time to engraftment, days

12

(%)
(0–101)

Graft-versus-host disease requiring treatment

336

(76)

Death

231

(52)

Death from underlying disease
Death from infection
Autopsy performed
Autopsy evidence of fungal infection

102

(44)

49

(21)

24

(5)

4

(1)

Syndrome
Pneumonia

26

(49)

Bloodstream infection

18

(34)

Sinusitis

4

(8)

Disseminated

4

(8)

Central nervous system

1

(2)

a

Fifty-three infections among 48 patients.

had disseminated infection, 2 had pneumonia, 1 had viremia,
and 1 had gastroenteritis. Of the 49 patients with respiratory viral
infections, 6 (12%) died within 14 days of infection.
Thirteen patients developed VZV infection, 11 of whom
had dermatomal skin lesions. One patient had disseminated
disease, and 1 had VZV meningitis. Only 1 of these patients
was receiving antiviral prophylaxis at the time of VZV
infection. There were 2 documented cases of viral meningitis: the previously mentioned varicella zoster, and 1 due to
human-herpesvirus 6.
Fungal Infections

A total of 53 IFI (18 probable and 35 proven) occurred among
48 (11%) patients (Table 4). The median time to the development of IFI was 142 days (range, 14–666). There were 18 infections caused by yeasts (all candidemias), 32 mold infections,
and 3 infections with P jiroveci. None of the patients with P
jiroveci pneumonia were receiving prophylaxis at the time of
Table 5. Viral Infections in 444 Hematopoietic Cell Transplant Recipients
(n = 187)
Virus
Cytomegalovirus infection
Viremia only

N

(%)

154

(82)

148

(96)

Organ involvementa

6

(4)

Human herpes virus-6

21

(11)
(10)

Parainfluenza virus

18

Varicella zoster virus

13

(7)

Respiratory syncytial virus

13

(7)

Influenza A virus

12

(6)

Epstein-Barr virus

10

(5)

8

(4)

Herpes simplex virus
Adenovirus

6

(3)

Influenza B virus

3

(2)

a

One hepatitis, 1 pneumonia, 4 enteritis.
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diagnosis. There were no diagnosed cases of cryptococcosis or
endemic mycoses.
The median time from the diagnosis of IFI to death was
29 days (0–868), and among the 15 patients with data available, 60% died within 6 weeks of diagnosis. The most common
syndromes were as follows: pneumonia (n = 25), candidemia
(n = 18), sinusitis (n = 4), and disseminated infection (n = 4)
(Table 4). Mucorales infections were uncommon (n = 5). Of the
16 patients with candidemia, there were no cases of disseminated infection.
Outcomes

Of the entire cohort of 444 patients, 113 (26%) had relapse of
their underlying disease during the study period and 231 (52%)
died (Table 6). The median time from transplant to death was
167 days (range, 5–885). The cause of death was attributed to
the underlying disease in 102 (44%) patients, to infection in
49 (21%), and to other or unknown causes in 35%. Transfer
to an intensive care unit occurred for 162 (36%) of patients,
and, of those, 122 (75%) ultimately died. Most patients (86%)
who required mechanical ventilation did not survive. Dialysis
occurred in 36 (8%) patients, and 25 (69%) of these patients died.
DISCUSSION

We report results from a large prospective, multicenter study
that examined all infectious complications after allogeneic HCT.
Infection is a substantial cause of morbidity and mortality and
was the second most common cause of death after relapse of
the underlying malignancy. Our study reveals suggests that several interventions have been successful in preventing infection
after HCT. Only 1% of patients developed a CMV infection with
organ involvement, likely attributable to antiviral prophylaxis.
Cytomegalovirus pneumonia, which was a major cause of mortality in the era before prophylaxis or early treatment strategies
[12], was seen in only 1% of our cohort. Likewise, the frequencies of herpes simplex virus, VZV, and human herpes virus-6
infections were very low, consistent with effective prophylactic strategies, although it should be noted that routine screening for these infections was not part of the study and that less
severe infections may have been missed. Pneumocystis jiroveci
pneumonia was seen in less than 1% of patients and occurred
only when prophylaxis was not used. There were no cases of
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Exophiala
Alternaria

Table 6.

Current antifungal strategies are relatively effective at preventing candidemia, but rates of invasive mold infection remain
constant [4]. Similar to other reports, the median time to an
IFI was 142 days, a time when most HCT recipients are outpatients [4, 5, 45, 48]. Death occurred within 6 weeks of IFI in
60%, highlighting the need for early diagnosis and improved
prophylaxis and treatment. There have been several reports of a
rise in infections with the Mucorales in this population [49–53]
and an association with the prophylactic use of triazoles such as
voriconazole, which lack activity against these agents [48, 50]. In
our cohort, these infections were extremely rare. The difficulty
in establishing the diagnosis of invasive mold infection in this
population is well recognized, and it is possible that our rates
underestimate the true incidence. We found that there were few
survivors among patients who required mechanical ventilation
or dialysis after hematopoietic stem cell transplant, in keeping
with known high mortality rates in patients who require ICU
admission or have evidence of multiorgan failure [54–57].
Our study has several limitations. We were able to enroll
only 48% of the transplants that were performed at our centers
over the study period. Because we did not collect data on
the nonparticipants, we do not know how representative our
patients were of the total population. Our study was limited
by the recognized difficulties in establishing proven infection
in this population. We did not collect granular data on GVHD
severity, duration, and treatment. Neutropenia and GVHD
are well known risk factors for many of the infectious complications after allogeneic HCT. Although we were not able to
examine these risk factors, we believe that our results provide
an important snapshot of the incidence of infectious disease
events after HCT from diverse geographic settings and prospective data collection. In addition, we lacked data on many
important noninfectious complications that may have influenced the risk for infection. The difficulty in ascertaining the
cause of death in this population with multiple comorbidities
and complications is a recognized problem as well. Because we
lacked detailed data on GVHD, it is possible that some patients
who died with infection really had GVHD as the cause of
death. Finally, it should be noted that 95% of our population
was white, and it is unclear whether rates of infection in our
centers, which although geographically diverse, are generalizable to other transplant settings.
CONCLUSIONS

Several important areas for future investigation are highlighted
by our study. Risk factors for bacteremia and C difficile infections that occur before engraftment should be examined to
help inform prophylactic strategies during different stages of
immune reconstitution post-HCT. Further information on the
timing and type of environmental exposures that lead to invasive mold infection is needed to prevent these devastating infections. A more individualized and granular understanding of the
Infections After Hematopoietic Cell Transplant • OFID • 5
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toxoplasmosis, nocardiosis, endemic mycoses, or mycobacterial
infection diagnosed in our cohort, in agreement with low rates
of these infections reported previously [13–20].
In contrast to lower frequencies of viral and P jiroveci
infections observed, the rates of bacteremia remain high.
Most occurred before engraftment. Consistent with previous studies, Gram-positive bacteremias were more common
than Gram-negatives, likely due to the association of Grampositive organisms with central venous catheters [21–23].
Several recent studies suggest that the ratio of Gram-positive
to Gram-negative bacteremias has been decreasing [23–25].
Pseudomonas aeruginosa remains the most common etiology
of Gram-negative bloodstream infections despite the standard
use of anti-pseudomonal β-lactam agents as empiric therapy for
neutropenic fever. Others have variably reported Escherichia coli
as the most common Gram-negative pathogen [3, 23, 26–28],
or Pseudomonas [1, 24]. This finding is particularly concerning
given that the 7-day mortality from Gram-negative bacteremia
was approximately 50%, which is more than 3-fold higher than
for Gram-positive bacteremia. We were not able to analyze antimicrobial resistance patterns to determine what proportion of
these infections represented failure of empiric therapy.
The most common bacterial infectious complication was
C difficile, which occurred in one third of patients. This rate
is higher than that reported in other inpatient populations. A
review of US hospital admissions in 2009 found a CDI diagnosis in 0.9% of patients [29]. The overall incidence of CDI in the
United States in 2011 was 7.4 per 10 000 patient days and represented 12.1% of all healthcare-associated infections [30, 31].
Others have similarly reported a higher incidence of CDI in the
HCT population with incidence rates varying from 4% to 13%
[32–36]. Clostridium difficile infections most often occurred
before engraftment, suggesting that neutropenia, more intense
exposure to antimicrobials and immunosuppression, and transmission in the hospital environment are likely to be important
risk factors. Another study is underway using this cohort and
a parallel cohort of lung transplant recipients from OTIP to
provide more detail on risk factors and outcomes for CDI. The
association of CDI with GVHD of the gastrointestinal tract has
been previously reported, and further study is needed in this
area [32, 36–38].
Respiratory viral infections were more frequent than
expected, which may be a result of increased access to testing
in both inpatient and outpatient settings and ease and rapidity of current molecular detection methods. They occurred in
11% of our cohort, compared with previously reported rates of
1.8%–4.3% [9, 39, 40]. Approximately half of patients with these
infections developed pneumonia or disseminated disease. It is
well known that geographic and seasonal factors are important
as well as transmission within the hospital environment [4, 5,
41–47]. Further studies will be important to tease out the effects
of these factors.

state of immunosuppression in an individual patient will allow
a finer stratification of risk for infection.
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